Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART123 as Monotherapy or With Ruxolitinib in Relapsed/Refractory AML
NCT07464951Phase 1Recruiting
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CART123 in acute myeloid leukemia (AML) (2 cohorts). Primary endpoints: Evaluate the Safety of CART123 at 5 years, Safety of CART123 in combination with Ruxolitinib at 5 years and 1 more. Started May 2026; status: recruiting.
02
Drugs
CART123
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07464951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07464951.